ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer

Gynecologic Oncology

Volumn 120, Issue 2, 2011, Pages 275-279

  Park, Jong Sup ^a   Jeon, Eun Kyung ^a   Chun, Sang Hoon ^a   Won, Hye Seong ^a   Lee, Ahwon ^a   Hur, Soo Young ^a   Lee, Keun Ho ^a   Bae, Seog Nyeon ^a   Yoon, Sei Chul ^a   Hong, Sook Hee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

ERCC1; Neoadjuvant chemotherapy; Uterine cervix cancer 2B

Indexed keywords

CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; ETOPOSIDE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; UTERINE CERVICAL NEOPLASMS;

EID: 79251596430     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.10.034     Document Type: Article

References (23)

1. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol Dec 10 2008;26(35):5802-12.
2. P. Suprasert, J. Srisomboon, and T. Kasamatsu Radical hysterectomy for stage IIB cervical cancer: a review Int J Gynecol Cancer 15 6 Nov-Dec 2005 995 1001
3. A. Gonzalez-Martin, L. Gonzalez-Cortijo, N. Carballo, J.F. Garcia, F. Lapuente, and A. Rojo The current role of neoadjuvant chemotherapy in the management of cervical carcinoma Gynecol Oncol 110 3 Suppl 2 Sep 2008 S36 S40
4. P. Benedetti-Panici, S. Greggi, A. Colombo, M. Amoroso, D. Smaniotto, and D. Giannarelli Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study J Clin Oncol 20 1 Jan 1 2002 179 188
5. A. Buda, R. Fossati, N. Colombo, F. Fei, I. Floriani, and D. Gueli Alletti Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study J Clin Oncol 23 18 Jun 20 2005 4137 4145
6. A.A. Lissoni, N. Colombo, A. Pellegrino, G. Parma, P. Zola, and D. Katsaros A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study Ann Oncol 20 4 Apr 2009 660 665
7. J.E. Sardi, A. Giaroli, C. Sananes, M. Ferreira, A. Soderini, and A. Bermudez Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results Gynecol Oncol 67 1 Oct 1997 61 69
8. T. Thigpen, H. Shingleton, H. Homesley, L. Lagasse, and J. Blessing Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group Cancer 48 4 Aug 15 1981 899 903
9. K.A. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. Andre, and V. Haddad DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 10 Sep 7 2006 983 991
10. E. Reed Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy Cancer Treat Rev 24 5 Oct 1998 331 344
11. A. Sancar Mechanisms of DNA excision repair Science 266 5193 Dec 23 1994 1954 1956
12. M. Dabholkar, J. Vionnet, F. Bostick-Bruton, J.J. Yu, and E. Reed Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy J Clin Invest 94 2 Aug 1994 703 708
13. M. Dabholkar, F. Bostick-Bruton, C. Weber, V.A. Bohr, C. Egwuagu, and E. Reed ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients J Natl Cancer Inst 84 19 Oct 7 1992 1512 1517
14. R.A. Britten, D. Liu, A. Tessier, M.J. Hutchison, and D. Murray ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells Int J Cancer 89 5 Sep 20 2000 453 457
15. R.V. Lord, J. Brabender, D. Gandara, V. Alberola, C. Camps, and M. Domine Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 7 Jul 2002 2286 2291
16. J.H. Bae, S.J. Lee, A. Lee, Y.G. Park, S.N. Bae, and J.S. Park Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer Gynecol Oncol 111 3 Dec 2008 444 448
17. I.U. De Silva, P.J. McHugh, P.H. Clingen, and J.A. Hartley Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells Mol Cell Biol 20 21 Nov 2000 7980 7990
18. L.J. Niedernhofer, H. Odijk, M. Budzowska, E. van Drunen, A. Maas, and A.F. Theil The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks Mol Cell Biol 24 13 Jul 2004 5776 5787
19. C.H. Choi, S.Y. Song, H. Kang, Y.Y. Lee, C.J. Kim, and J.W. Lee Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy J Obstet Gynaecol Res 36 2 Apr 2010 304 310
20. C.H. Choi, S.Y. Song, J.J. Choi, Y.A. Park, H. Kang, and T.J. Kim Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy BMC Cancer 8 2008 295
21. S. Costa, P. Terzano, A. Bovicelli, A. Martoni, B. Angelelli, and D. Santini CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma Gynecol Oncol 80 1 Jan 2001 67 73
22. Y. Nio, S. Imai, T. Shiraishi, M. Tsubono, H. Morimoto, and C.C. Tseng Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay Cancer 65 6 Mar 15 1990 1273 1278
23. T. Furukawa, T. Kubota, H. Tanino, S. Oura, S. Yuasa, and H. Murate Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay Anticancer Res 20 5C Sep-Oct 2000 3657 3658